After central testing for EGFR mutations , treatment-naive patients ( stage IIIB or IV cancer -LSB- American Joint Committee on Cancer version @ -RSB- , performance status @-@ ) were randomly assigned ( @:@ ) to receive either oral afatinib ( @ mg per day ) or intravenous gemcitabine @ mg/m ( @ ) on day @ and day @ plus cisplatin @ mg/m ( @ ) on day @ of a @-week schedule for up to six cycles .